ArticleJAMA dermatology2025
Skin Cancer Surveillance Program for Solid Organ Transplant Recipients.
Article in JAMA dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Objectively Measured Photoaging and Skin Cancer in Organ Transplant Recipients.Acta dermato-venereologica · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Solid organ transplant (SOT) recipients are at increased risk for skin cancer due to long-term immunosuppression. However, this risk is heterogeneous across the SOT population. The Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) incorporates established clinical risk factors to stratify SOT recipients into low-, medium-, high-, and very high-risk groups for posttransplant skin cancer. Objective: To assess skin cancer risk among SOT recipients and to evaluate the impact of a modified SUNTRAC-based surveillance program on screening rates, skin cancer incidence, and health care resource utilization. Design, Settings, and Participants: This was a retrospective cohort study of adult patients (≥18 years) who underwent SOT from January 1, 2016, to March 31, 2023. SOT recipients and nonrecipients were identified from the transplant registry of Kaiser Permanente Northern California (KPNC), an integrated health care delivery system providing care to more than 4.5 million members. SOT recipients were matched 1:20 on sex, race and ethnicity, and medical facility with nonrecipients. The study period was divided into preimplementation of the modified SUNTRAC (ie, KP-SUNTRAC) program (2016-2021) and postimplementation (2022-2024) periods. Included participants were followed up through March 31, 2024. Data were analyzed from July 2024 to June 2025. Exposure: Implementation of KP-SUNTRAC risk-based skin cancer surveillance program. Main Outcomes and Measures: Among SOT recipients, the number of skin cancer screenings; skin cancer incident rates for basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, or Merkel cell carcinoma; and health care resource utilization, measured by dermatology and nondermatology encounters and pathology specimen counts. Results: The analysis included 2083 SOT recipients matched with 26 199 nonrecipients and found a 7.8-fold increased risk of developing skin cancer posttransplant among the SOT recipients compared with nonrecipients (hazard ratio [HR], 7.78; 95% CI, 5.97-10.10). After KP-SUNTRAC implementation, the risk of first detected skin cancer was significantly higher in the postimplementation group (HR, 2.57; 95% CI, 1.76-3.73). During the postimplementation period, screening rates significantly improved among the high-risk (HR, 1.98; 95% CI, 1.39-2.82) and very high-risk (HR, 2.17; 95% CI, 1.21-3.86) groups compared with preimplementation. Health care utilization did not increase after KP-SUNTRAC implementation. Conclusions and Relevance: This cohort study found that KP-SUNTRAC was associated with improved skin cancer screening rates and detection among SOT recipients at higher risk of developing skin cancer, without increasing short-term health care utilization. This targeted surveillance approach supports timely diagnosis and has the potential to reduce morbidity and future health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.